Website stats and analysis

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of . These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guar...

2.48 Rating by Usitestat

mrknewsroom.com was registered 7 years 9 months ago. It is a domain having .com extension. It is estimated worth of $ 8.95 and have a daily income of around $ 0.15. As no active threats were reported recently, mrknewsroom.com is SAFE to browse.

Traffic Report

Daily Unique Visitors: Not Applicable
Daily Pageviews: Not Applicable

Estimated Valuation

Income Per Day: $ 0.15
Estimated Worth: $ 8.95

Search Engine Indexes

Google Indexed Pages: Not Applicable
Yahoo Indexed Pages: Not Applicable
Bing Indexed Pages: Not Applicable

Search Engine Backlinks

Google Backlinks: Not Applicable
Bing Backlinks: Not Applicable
Alexa BackLinks: Not Applicable

Safety Information

Google Safe Browsing: No Risk Issues
Siteadvisor Rating: Not Applicable
WOT Trustworthiness: Very Poor
WOT Privacy: Very Poor
WOT Child Safety: Very Poor

Website Ranks & Scores

Alexa Rank: Not Applicable
PageSpeed Score: 89 ON 100
Domain Authority: 49 ON 100
Bounce Rate: Not Applicable
Time On Site: Not Applicable

Web Server Information

Hosted IP Address:

192.0.66.224

Hosted Country:

United States US

Location Latitude:

37.7484

Location Longitude:

-122.414

Traffic Classification

Total Traffic: No Data
Direct Traffic: No Data
Referral Traffic: No Data
Search Traffic: No Data
Social Traffic: No Data
Mail Traffic: No Data
Display Traffic: No Data

Search Engine Results For mrknewsroom.com

Merck Announces FDA Approval for ERVEBO ... - Merck Vaccines

- https://www.merckvaccines.com/wp-content/uploads/sites/8/2020/03/MerckAnnouncesFDAApprovalforERVEBO®EbolaZaireVaccineLive.pdf

Dec 20, 2019 ... Published on Merck Newsroom Home (https://www.mrknewsroom.com) on 12/20/19 7:15 am EST. Merck Announces FDA Approval for ERVEBO® (Ebola.


Diagnosis & Tests for Melanoma - Virginia Cancer Institute

- https://www.vacancer.com/cancer/melanoma/diagnosis-tests-for-melanoma/

Aug 14, 2020 ... Merck website. Available at: https://www.mrknewsroom.com/news-release/oncology-newsroom/mercks-pivotal-keynote-006-study-first ...


FDA Approves Doravirine (Pifeltro) and New FDC With TDF/3TC ...

- https://www.thebodypro.com/article/fda-approves-doravirine-pifeltro-and-new-fdc-with-

Aug 31, 2018 ... www.mrknewsroom.com; ClinicalTrials.gov. MK-8591 with doravirine and lamivudine in participants infected with HIV type 1 (MK-8591-011) ...


Pembrolizumab for the Treatment of Hepatocellular Carcinoma ...

- https://www.karger.com/Article/Fulltext/500143

... https://www.mrknewsroom.com/news-release/oncology/merck-provides-update-keynote-240-phase-3-study-keytruda-pembrolizumab-previou (accessed February 19, ...


We need a coronavirus vaccine — I just wish we could afford it ...

- https://thehill.com/opinion/healthcare/488646-we-need-a-coronavirus-vaccine-i-just-wish-we-could-afford-it

Mar 20, 2020 ... https://www.mrknewsroom.com... Ken • 1 year ago. Everyone knows what went wrong in South Africa... Guest • 1 year ago. Guest • 1 year ago.


FDA Approval of Anti-Cancer Drug | Mesothelioma Help

- https://www.mesotheliomahelp.org/fda-anti-cancer-drug-biomarker-encouraging-patients/

http://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-keytruda-pembrolizumab-adult-and-pediatr; Keytruda website


Theron Leonce (@TheronLeonce) | Stocktwits

- https://stocktwits.com/TheronLeonce/message/226494590

Jul 9, 2020 ... Merck announcement listed below: https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/Merck-Announces-Appointment-of-Organon ...


FDA aprueba pembrolizumab en 1L de cáncer colorrectal MSI-H o ...

- https://sciencelink.com/single-noticia.php?id=3597

Jun 30, 2020 ... ... https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-First-Line-Treatment ...


FDA approves Dificid for C. difficile treatment in children - Healio

- https://www.healio.com/news/pediatrics/20200127/fda-approves-dificid-for-c-difficile-treatment-in-children

Jan 27, 2020 ... ... older. https://www.mrknewsroom.com/news-release/prescription-medicine-news/fda-approves-mercks-dificid-fidaxomicin-treat-clostridioides.


Pembrolizumab in Patients With Metastatic Breast Cancer With High ...

- https://ascopubs.org/doi/10.1200/JCO.20.02923

Apr 12, 2021 ... ... in Previously-Treated Patients with Metastatic Triple-Negative Breast Cancer. https://www.mrknewsroom.com/news-release/oncology/merck- ...


Media - Merck.com

- https://www.mrknewsroom.com/

Merck's online newsroom offers real-time news about Merck's prescription medicines, vaccines and consumer care products.


Trial Investigators Discuss FDA Draft Guidance on Master Protocols

- https://www.targetedonc.com/view/trial-investigators-discuss-fda-draft-guidance-on-master-protocols

Nov 30, 2018 ... ... September27, 2015. mrknewsroom.com/news-release/oncology-newsroom/new-data-keynote-028-mercks-trial-evaluating-keytruda-pembrolizumab-a.


Practice-Changing Advances in the Adjuvant Treatment of Melanoma

- https://www.targetedonc.com/view/practicechanging-advances-in-the-adjuvant-treatment-of-melanoma

May 30, 2018 ... ... 2018. www.mrknewsroom.com/news-release/oncology/mercks-keytruda-pembrolizumab-significantly-improved-recurrence-free-survival-.


Access the 2020 Prioritisation Report - Medicines Patent Pool

- https://medicinespatentpool.org/uploads/2021/01/Prioritisation_Report_2020.pdf

21 https://www.mrknewsroom.com/news-release/research-and-development-news/merck-presents-early-evidence-extended-delivery-investiga.


oup_inthea_ihx038 3..6 ++ - Oxford Academic Journals

- https://academic.oup.com/inthealth/article-pdf/10/suppl_1/i3/24509016/ihx038.pdf

http://www.mrknewsroom.com/news-release/ · corporate-news/merck-and-mectizan-donation-program-donate-1- · million-end-fund-efforts-he [accessed 1 June 2017]. 14 ...


The Nobel Prize: Checkpoint Inhibitors

- https://www.ajmc.com/view/the-nobel-prize-checkpoint-inhibitors

Oct 18, 2018 ... mrknewsroom.com/news-release/prescription-medicine-news/merck-receives-accelerated-approv- 9. al-keytruda-pembrolizumab-f. Accessed October 2, ...


Pfizer and Merck's Steglatro for type 2 diabetes: a valuable...

- https://clarivate.com/blog/pfizer-mercks-steglatro-type-2-diabetes-valuable-addition-rapidly-rising-sglt-2-inhibitor-market/

Jun 7, 2018 ... 4 http://www.mrknewsroom.com/news-release/corporate-news/fda-approves-sglt2-inhibitor-steglatro-ertugliflozin-and-fixed-dose-comb.


HIV Clinical Updates: New Single-Tablet Regimens - Jamielynn C ...

- https://journals.sagepub.com/doi/abs/10.1177/1060028018793252

... of HIV-1 infection. http://www.mrknewsroom.com/news-release/corporate-news/fda-accepts-new-drug-applications-mercks-doravirine-companys-investigati.


Published by HIV i-Base htb supplement: 2019 Vol 20:(1) New drugs ...

- http://i-base.info/htb/wp-content/uploads/2019/07/PIPELINE-2019-FINAL-full-version.pdf

Jul 10, 2019 ... https://www.mrknewsroom.com. 5. Merck (MSD) press release. FDA approves Merck's Delstrigo (doravirine/ lamivudine/tenofovir disoproxil ...


Odanacatib: the best osteoporosis treatment we never had? - The ...

- https://www.thelancet.com/journals/landia/article/PIIS2213-8587(19)30348-1/fulltext

Oct 29, 2019 ... Merck provides update on odanacatib development program.Sept 2, 2016. Merck Newsroom Home. https://www.mrknewsroom.com/news-release/research-and ...

Page Resources Breakdown

Homepage Links Analysis

Media - Merck.com
Merck's online newsroom offers real-time news about Merck's prescription medicines, vaccines and consumer care products.

Website Inpage Analysis

H1 Headings: 3 H2 Headings: 4
H3 Headings: 11 H4 Headings: 1
H5 Headings: Not Applicable H6 Headings: Not Applicable
Total IFRAMEs: 1 Total Images: 23
Google Adsense: Not Applicable Google Analytics: Not Applicable

Two Phrase Analysis

Words Occurrences Density Possible Spam
of the 9 0.735 % No
2021 Merck 8 0.654 % No
in the 8 0.654 % No
United States 5 0.408 % No
the United 5 0.408 % No
the company’s 5 0.408 % No
States and 4 0.327 % No
of Merck 4 0.327 % No
Merck Co 4 0.327 % No
KEYTRUDA® pembrolizumab 4 0.327 % No
Co Inc 4 0.327 % No
Oncologic Drugs 3 0.245 % No
Drugs Advisory 3 0.245 % No
health care 3 0.245 % No
products and 3 0.245 % No
Advisory Committee 3 0.245 % No
and Canada 3 0.245 % No
releases Company 3 0.245 % No
News releases 3 0.245 % No
Company statements 3 0.245 % No

Four Phrase Analysis

Words Occurrences Density Possible Spam
the United States and 4 0.327 % No
of Merck Co Inc 3 0.245 % No
in the United States 3 0.245 % No
United States and Canada 3 0.245 % No
Oncologic Drugs Advisory Committee 3 0.245 % No
Inc Kenilworth NJ USA 3 0.245 % No
Co Inc Kenilworth NJ 3 0.245 % No
Merck Co Inc Kenilworth 3 0.245 % No
Drugs Advisory Committee ODAC 2 0.163 % No
2021 Merck Statement on 2 0.163 % No
News releases Company statements 2 0.163 % No
differ materially from those 2 0.163 % No
in the forwardlooking statements 2 0.163 % No
of the United States 2 0.163 % No
FDA’s Oncologic Drugs Advisory 2 0.163 % No
NJ USA This news 1 0.082 % No
This news release of 1 0.082 % No
Kenilworth NJ USA This 1 0.082 % No
USA This news release 1 0.082 % No
reserved Forwardlooking statement of 1 0.082 % No

Websites Hosted on Same IP (i.e. 192.0.66.224)

Industrial Automation Tooling Systems & Products | ATS Automation

- atsautomation.com

ATS Automation's industrial automation systems provide the perfect synergy of experience, automation technology & scale. Advance your factory automation today.

  162,586   $ 76,800.00

Página principal - MSD Salud Animal México

- msd-salud-animal.mx

MSD Salud Animal es una empresa global, enfocada en la investigación, el desarrollo y manufactura de medicamentos y servicios veterinarios.

  1,430,082   $ 960.00

HTTP Header Analysis

Http-Version: 1.1
Status-Code: 200
Status: 200 OK
Server: nginx
Date: Sun, 25 Jul 2021 07:32:30 GMT
Content-Type: text/html; charset=UTF-8
Content-Length: 20444
Connection: keep-alive
Host-Header: a9130478a60e5f9135f765b23f26593b
X-Frame-Options: DENY
Link: ; rel=shortlink
Content-Encoding: gzip
X-rq: hhn2 0 4 9980
Age: 223
X-Cache: hit
Cache-Control: private, no-store
Accept-Ranges: bytes
Strict-Transport-Security: max-age=31536000;includeSubdomains;preload

Domain Information

Domain Registrar: MarkMonitor Inc.
Registration Date: 2017-02-07 7 years 9 months 1 week ago
Last Modified: 2020-01-06 4 years 10 months 1 week ago

Domain Nameserver Information

Host IP Address Country
cbru.br.ns.els-gms.att.net 68.94.156.132 United States United States
cmtu.mt.ns.els-gms.att.net 99.99.99.132 United States United States
ns6.customer.level3.net 209.244.4.85 United States United States
ns9.customer.level3.net 209.244.4.148 United States United States

DNS Record Analysis

Host Type TTL Extra
mrknewsroom.com A 296 IP: 192.0.66.224
mrknewsroom.com NS 86400 Target: ns9.customer.level3.net
mrknewsroom.com NS 86400 Target: cbru.br.ns.els-gms.att.net
mrknewsroom.com NS 86400 Target: cmtu.mt.ns.els-gms.att.net
mrknewsroom.com NS 86400 Target: ns6.customer.level3.net
mrknewsroom.com SOA 86400 MNAME: cbru.br.ns.els-gms.att.net
RNAME: rm-hostmaster.ems.att.com
Serial: 12
Refresh: 3600
Retry: 1200
Expire: 604800
mrknewsroom.com TXT 86400 TXT: v=spf1 -all

Full WHOIS Lookup

Domain Name: MRKNEWSROOM.COM
Registry Domain ID:
2095948720_DOMAIN_COM-VRSN
Registrar WHOIS Server:
whois.markmonitor.com
Registrar URL:
http://www.markmonitor.com
Updated Date:
2020-01-06T10:09:07Z
Creation Date:
2017-02-07T04:21:50Z
Registry Expiry Date:
2022-02-07T04:21:50Z
Registrar: MarkMonitor Inc.
Registrar
IANA ID: 292
Registrar Abuse Contact Email:
[email protected]
Registrar Abuse Contact Phone:
+1.2083895740
Domain Status: clientDeleteProhibited
https://icann.org/epp#clientDeleteProhibited
Domain Status:
clientTransferProhibited
https://icann.org/epp#clientTransferProhibited
Domain Status:
clientUpdateProhibited
https://icann.org/epp#clientUpdateProhibited
Name Server:
CBRU.BR.NS.ELS-GMS.ATT.NET
Name Server:
CMTU.MT.NS.ELS-GMS.ATT.NET
Name Server:
NS6.CUSTOMER.LEVEL3.NET
Name Server:
NS9.CUSTOMER.LEVEL3.NET
DNSSEC: unsigned
URL of the ICANN
Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>>
Last update of whois database: 2021-07-25T07:32:14Z

Similarly Ranked Websites

Google Chrome - Download the Fast, Secure Browser from Google

- chrome.google.com

Get more done with the new Google Chrome. A more simple, secure, and faster web browser than ever, with Google’s smarts built-in. Download now.

1   $ 16,097,351,400.00

YouTube

- youtube.com

Share your videos with friends, family, and the world

2   $ 8,048,676,240.00

Log into Facebook

- facebook.com

Log into Facebook to start sharing and connecting with your friends, family, and people you know.

4   $ 4,024,338,120.00

腾讯网

- qq.com

腾讯网从2003年创立至今,已经成为集新闻信息,区域垂直生活服务、社会化媒体资讯和产品为一体的互联网媒体平台。腾讯网下设新闻、科技、财经、娱乐、体育、汽车、时尚等多个频道,充分满足用户对不同类型资讯的需求。同时专注不同领域内容,打造精品栏目,并顺应技术发展趋势,推出网络直播等创新形式,改变了用户获取资讯的方式和习惯。

5   $ 3,219,470,280.00

Amazon.com. Spend less. Smile more.

- amazon.com

Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and...

7   $ 2,299,621,320.00